" class="no-js "lang="en-US"> Bruce Henderson - Medtech Alert
Saturday, September 23, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Bruce Henderson

Bruce Henderson

About Bruce Henderson

Physician and Founder/CEO of Altair Medical, a digital health company developing an innovative platform for the capture and analysis of longitudinal respiratory data. We use this data to derive metrics with clinical utility in acute and chronic respiratory conditions.

Related Story

Fundraising

 Altair Medical Secures $3.1m in Pre-Series A financing | Pharmtech Focus

Altair Medical Secures $3.1m in Pre-Series A financing

April 19 2021

UK based Altair Medical today announced it has secured £2.25m ($3.1m) of Pre-Series A funding […]